Long‐term cost‐effectiveness of tirzepatide for individuals with type 2 diabetes and comorbid obesity
Authors' conclusion
Compared with placebo, both TZP 15 mg and 10 mg QW are cost-effective options for individuals with T2D and comorbid obesity.
Study context
- Population
- Individuals with T2D and comorbid obesity in the United States (US)
- Comparison
- Tirzepatide 10 and 15 mg QW vs placebo
- Outcome
- QALYs, life-years, costs and ICER vs placebo
- Follow-up
- 30-year time horizon
Methodological detailsmodelling study, Building, Relating, Assessing and Validating Outcomes (BRAVO) Diabetes Model, US healthcare perspective, 30-year time horizon, treatment effects from SURMOUNT-2 trial, assumed to persist 5 years, one-way and probabilistic sensitivity analyses, willingness-to-pay (WTP) threshold $100 000 per quality-adjusted life year (QALY) gained
- Modelling study
- BRAVO Diabetes Model
- US healthcare perspective
- 30-year time horizon
- Treatment effects from SURMOUNT-2 trial, assumed to persist 5 years
- One-way and probabilistic sensitivity analyses
- WTP threshold $100 000 per QALY gained
Main finding
As reported in the abstract
- Tirzepatide (TZP) 15 mg QW vs placebo: QALYs gained
- 0.69
- TZP 15 mg QW vs placebo: life-years gained
- 0.58
- TZP 15 mg QW vs placebo: cost saving
- $1409
- TZP 10 mg QW vs placebo: QALYs gained
- 0.60
- TZP 10 mg QW vs placebo: life-years gained
- 0.49
- TZP 10 mg QW vs placebo: increased costs
- $1855
- TZP 10 mg QW vs placebo: ICER
- $3092 per QALY
Further findings
- Probability of cost-effectiveness, TZP 15 mg QW
- 98.9%
- Sensitivity analysis confirmed the robustness of results
- Probability for TZP 10 mg QW printed ambiguously (98.9% and 98.5%)
Original publication
Long‐term cost‐effectiveness of tirzepatide for individuals with type 2 diabetes and comorbid obesity. Diabetes Obes Metab. Published 2 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →